Routine treatment

ApprovedSmall molecule

GSK

Routine treatment is one of 59 small molecule programs targeting Type 2 Diabetes. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Type 2 DiabetesActive, not recruiting

AsthmaActive, not recruiting

Irritable Bowel Syndrome (IBS)Recruiting

Type 2 DiabetesPreclinical

Active, not recruiting

AsthmaApproved

Active, not recruiting

Irritable Bowel Syndrome (IBS)Preclinical

Recruiting

Competition

Competitive Landscape

1050 competitors in Asthma

#DrugCompanyPhaseTrials

Routine treatment

GSK

Approved

1 2

Veramyst

GSK

Preclinical

46 3

Xolair

Roche

Preclinical

25 4

Singulair

AstraZeneca

Preclinical

17 5

Nucala

GGlaxo Dba Glaxosmithkline

Preclinical

35 6

Cinqair

Teva

Preclinical

13 7

Dupixent

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

30 8

Asmanex

Novartis

Preclinical

5 9

Celexa

AbbVie

Preclinical

1 10

Spiriva

Boehringer Ingelheim

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 3Recruiting

CTEPH

NCT06922240

Q1 2029

PreclinicalRecruiting

Irritable Bowel Syndrome (IBS)

NCT07635394

Clinical

Trials by Indication[1]

Type 2 Diabetes1 trial

Determining the Effect of Vitamin D, Dyslipidemia and Microvascular in Patients With Type 2 Diabetes

Completed·—·N/A·NCT04439474·187 enrolled

Asthma1 trial

Asthma Control Test Guided Treatment in Chinese Subjects

Completed· GSK logo

GSK·Phase 4·NCT02868281·530 enrolled

Prevention1 trial

Cardio-Cerebrovascular Co-Prevention and Co-Management Based on Internet+

Unknown status·NNanfang Hospital, Southern Medical University·N/A·NCT04409210·8,840 enrolled

CTEPH1 trial

Riociguat-Discontinue Effects on Right HEART in CTEPH (RED-HEART)

Recruiting·SSuqiao Yang·Phase 3·NCT06922240·68 enrolled

Irritable Bowel Syndrome (IBS)1 trial

Efficacy and Safety of Pregabalin in Patients With Irritable Bowel Syndrome : A Multi-center Prospective Randomized Open Blinded End-point Trial

Recruiting·BBeijing Tiantan Hospital·Preclinical·NCT07635394·258 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Routine treatment. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Routine treatment compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Routine treatment. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: GSK

Routine treatment

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q1 2029

Trials by Indication[1]

Type 2 Diabetes1 trial

Asthma1 trial

Prevention1 trial

CTEPH1 trial

Irritable Bowel Syndrome (IBS)1 trial

References

Drug Info

Quick Facts

Related News